Pharmacological Inhibition of Chitotriosidase (CHIT1) as a Novel Therapeutic Approach for Sarcoidosis

References

• Hunninghake GW, Costabel U, Ando M. Statement on sarcoidosis. Am J Respir Crit Care Med. 1999;160:736–755. doi:10.1164/ajrccm.160.2.ats4-99.
   PubMed Web of Science ®Google Scholar
• Grunewald J, Grutters JC, Arkema EV. Sarcoidosis. Nat Rev Dis Prim. 2019. doi:10.1038/s41572-019-0096-x
   Web of Science ®Google Scholar
• Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU. Pulmonary sarcoidosis. Lancet Respir Med. 2018;6:389–402. doi:10.1016/S2213-2600(18)30064-X
   PubMed Web of Science ®Google Scholar
• Bennett D, Bargagli E, Refini RM, Rottoli P. New concepts in the pathogenesis of sarcoidosis. Expert Rev Respir Med. 2019;13:981–991. doi:10.1080/17476348.2019.1655401
   PubMed Web of Science ®Google Scholar
• Venet A, Hance AJ, Saltini C, Robinson BW, Crystal RG. Enhanced alveolar macrophage-mediated antigen-induced T lymphocyte proliferation in sarcoidosis. J Clin Invest. 1985;75:293–301. doi:10.1172/JCI111688
   PubMed Web of Science ®Google Scholar
• Zissel G, Müller-Quernheim J. Cellular players in the immunopathogenesis of sarcoidosis. Clin Chest Med. 2015;36:549–560. doi:10.1016/j.ccm.2015.08.016
   PubMed Web of Science ®Google Scholar
• Sakthivel P, Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr Opin Hematol. 2017;24:59–65. doi:10.1097/MOH.0000000000000301
   PubMed Web of Science ®Google Scholar
• Nunes H, Jeny F, Bouvry D. Indications for treatment of sarcoidosis. Curr Opin Pulm Med. 2019;25:505–518. doi:10.1097/MCP.0000000000000604
   PubMed Web of Science ®Google Scholar
• Boot RG, Hollak CEM, Verhoek M, Alberts C, Jonkers RE, Aerts JM. Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis. Clin Chim Acta. 2010;411:31–36. doi:10.1016/j.cca.2009.09.034
   PubMed Web of Science ®Google Scholar
• Bennett D, Cameli P, Lanzarone N. Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis. Respir Res. 2020. doi:10.1186/s12931-019-1263-z
   Web of Science ®Google Scholar
• Cho SJ, Weiden MD, Lee CG. Chitotriosidase in the pathogenesis of inflammation, interstitial lung diseases and COPD. Allergy Asthma Immunol Res. 2015;7:14–21. doi:10.4168/aair.2015.7.1.14
   PubMed Web of Science ®Google Scholar
• Przysucha N, Górska K, Krenke R. Chitinases and chitinase-like proteins in obstructive lung diseases – current concepts and potential applications. Int J Chron Obstruct Pulmon Dis. 2020;15:885–899. doi:10.2147/COPD.S236640
   PubMed Web of Science ®Google Scholar
• Chang D, Sharma L, Dela Cruz CS. Chitotriosidase: a marker and modulator of lung disease. Eur Respir Rev. 2020;29:190143. doi:10.1183/16000617.0143-2019
   PubMed Web of Science ®Google Scholar
• Seibold MA, Donnelly S, Solon M. Chitotriosidase is the primary active chitinase in the human lung and is modulated by genotype and smoking habit. J Allergy Clin Immunol. 2008;122:944–950. doi:10.1016/j.jaci.2008.08.023
   PubMed Web of Science ®Google Scholar
• Crouser ED, White P, Caceres EG. A novel in vitro human granuloma model of sarcoidosis and latent tuberculosis infection. Am J Respir Cell Mol Biol. 2017;57:487–498. doi:10.1165/rcmb.2016-0321OC
   PubMed Web of Science ®Google Scholar
• Koralewski R, Dymek B, Mazur M. Discovery of OATD-01, a first-in-class chitinase inhibitor as potential new therapeutics for idiopathic pulmonary fibrosis. J Med Chem. 2020;63:15527–15540. doi:10.1021/acs.jmedchem.0c01179
   PubMed Web of Science ®Google Scholar
• Sklepkiewicz P, Dymek BA, Mlacki M. Inhibition of CHIT1 as a novel therapeutic approach in idiopathic pulmonary fibrosis. Eur J Pharmacol. 2022;919:174792. doi:10.1016/j.ejphar.2022.174792
   PubMed Web of Science ®Google Scholar
• Crouser ED, Maier LA, Baughman RP. Diagnosis and detection of sarcoidosis an official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2020;201:E26–51. doi:10.1164/rccm.202002-0251ST
   PubMed Web of Science ®Google Scholar
• Proboszcz M, Paplińska-Goryca M, Nejman-Gryz P, Górska K, Krenke R. A comparative study of sTREM-1, IL-6 and IL-13 concentration in bronchoalveolar lavage fluid in asthma and COPD: a preliminary study. Adv Clin Exp Med. 2017;26:231–236. doi:10.17219/acem/64875
   PubMed Web of Science ®Google Scholar
• Osinka K, Zielińska-Krawczyk M, Korczyński P. Impact of endobronchial ultrasound guided transbronchial needle aspiration on diagnostic yield of bronchoscopy in patients with mediastinal lymph node enlargement. Adv Exp Med Biol. 2016;911:33–43 doi:10.1007/5584_2016_222.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 2001;25:402–408. doi:10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin DJ. Preferential migration of activated CD4 + and CD8 + T cells in response to MIP-1α and MIP-1β. Science. 1993;260:355–358. doi:10.1126/science.7682337
   PubMed Web of Science ®Google Scholar
• Capelli A, Stefano ADI, Lusuardi M, Gnemmi I, Donner C. Increased macrophage inflammatory protein-1α and macrophage inflammatory protein-1β levels in bronchoalveolar lavage fluid of patients affected by different stages of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2002;165:236–241. doi:10.1164/ajrccm.165.2.2106084
   PubMed Web of Science ®Google Scholar
• Bulfone-Paus S, Ungureanu D, Pohl T. Interleukin-15 protects from lethal apoptosis in vivo. Nat Med. 1997;3:1124–1128. doi:10.1038/nm1097-1124
   PubMed Web of Science ®Google Scholar
• Seder RA. High-dose IL-2 and IL-15 enhance the in vitro priming of naive CD4+ T cells for IFN-gamma but have differential effects on priming for IL-4. J Immunol. 1996;156:2413–2422.
   PubMed Web of Science ®Google Scholar
• Muro S, Taha R, Tsicopoulos A. Expression of IL-15 in inflammatory pulmonary diseases. J Allergy Clin Immunol. 2001;108:970–975. doi:10.1067/mai.2001.119556
   PubMed Web of Science ®Google Scholar
• Minasyan M, Sharma L, Pivarnik T. Elevated IL-15 concentrations in the sarcoidosis lung are independent of granuloma burden and disease phenotypes. Am J Physiol Lung Cell Mol Physiol. 2021;320:L1137–46. doi:10.1152/ajplung.00575.2020
   PubMed Web of Science ®Google Scholar
• Wang H, Jiang H, Teles RMB. Cellular, molecular, and immunological characteristics of Langhans multinucleated giant cells programmed by IL-15. J Invest Dermatol. 2020;140:1824–1836.e7. doi:10.1016/j.jid.2020.01.026
   PubMed Web of Science ®Google Scholar
• Teufel LU, Arts RJW, Netea MG, Dinarello CA, Joosten LAB. IL-1 family cytokines as drivers and inhibitors of trained immunity. Cytokine. 2022;150:155773. doi:10.1016/j.cyto.2021.155773
   PubMed Web of Science ®Google Scholar
• Cavalli G, Dinarello CA. Anakinra therapy for non-cancer inflammatory diseases. Front Pharmacol. 2018;9. doi:10.3389/fphar.2018.01157
   PubMed Web of Science ®Google Scholar
• Mikuniya T, Nagai S, Takeuchi M. Significance of the interleukin-1 receptor antagonist/interleukin-1β ratio as a prognostic factor in patients with pulmonary sarcoidosis. Respiration. 2000;67:389–396. doi:10.1159/000029536
   PubMed Web of Science ®Google Scholar
• Jeny F, Pacheco Y, Besnard V, Valeyre D, Bernaudin J-F. Experimental models of sarcoidosis. Curr Opin Pulm Med. 2016;22:492–499. doi:10.1097/MCP.0000000000000295
   PubMed Web of Science ®Google Scholar
• Huizar I, Malur A, Midgette YA. Novel murine model of chronic granulomatous lung inflammation elicited by carbon nanotubes. Am J Respir Cell Mol Biol. 2011;45:858–866. doi:10.1165/rcmb.2010-0401OC
   PubMed Web of Science ®Google Scholar
• Malur A, Barna BP. Exposure to a mycobacterial antigen, ESAT-6, exacerbates granulomatous and fibrotic changes in a multiwall carbon nanotube model of chronic pulmonary disease. J Nanomed Nanotechnol. 2015;06:777–783. doi:10.4172/2157-7439.1000340
   Google Scholar
• James AJ, Reinius LE, Verhoek M. Increased YKL-40 and chitotriosidase in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;193:131–142. doi:10.1164/rccm.201504-0760OC
   PubMed Web of Science ®Google Scholar
• Tong X, Wang D, Liu S. International journal of COPD dovepress the YKl-40 protein is a potential biomarker for COPD: a meta-analysis and systematic review. Int J COPD. 2018;13:409–418. doi:10.2147/COPD.S152655
   Google Scholar
• Zhou Y, Peng H, Sun H. Chitinase 3-like 1 suppresses injury and promotes fibroproliferative responses in mammalian lung fibrosis. Sci Transl Med. 2014;6:240ra76. doi:10.1126/scitranslmed.3007096
   PubMed Web of Science ®Google Scholar
• Uysal P, Durmus S, Sozer V. YKL-40, soluble IL-2 receptor, angiotensin converting enzyme and C-reactive protein: comparison of markers of sarcoidosis activity. Biomolecules. 2018;8:84. doi:10.3390/biom8030084
   PubMed Web of Science ®Google Scholar
• Rose CE, Sung SSJ, Fu SM. Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung. Microcirculation. 2003;10:273–288. doi:10.1080/mic.10.3-4.273.288
   PubMed Web of Science ®Google Scholar
• Palchevskiy V, Hashemi N, Weigt SS. Immune response CC chemokines CCL2 and CCL5 are associated with pulmonary sarcoidosis. Fibrogenes Tissue Repair. 2011;4. doi:10.1186/1755-1536-4-10
   PubMedGoogle Scholar
• Hamsten C, Wiklundh E, Grönlund H. Elevated levels of FN1 and CCL2 in bronchoalveolar lavage fluid from sarcoidosis patients. Respir Res. 2016;17:69. doi:10.1186/s12931-016-0381-0
   PubMed Web of Science ®Google Scholar
• Icer MA, Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. Clin Biochem. 2018;59:17–24. doi:10.1016/j.clinbiochem.2018.07.003
   PubMed Web of Science ®Google Scholar
• Lavi H, Assayag M, Schwartz A. The association between osteopontin gene polymorphisms, osteopontin expression and sarcoidosis. PLoS One. 2017;12:e0171945. doi:10.1371/journal.pone.0171945
   PubMed Web of Science ®Google Scholar
• Carlson I, Tognazzi K, Manseau EJ, Dvorak HF, Brown LF. Osteopontin is strongly expressed by histiocytes in granulomas of diverse etiology. Lab Investig. 1997;77:103–108.
   PubMed Web of Science ®Google Scholar